atai LIFE SCIENCES | Company Profile
NASDAQ: ATAI
Latest Sector Updates
atai is a biopharmaceutical company that leverages a decentralised platform approach to incubate and accelerate the development of highly effective mental health treatments that address unmet needs of patients.
atai was founded in 2018 as a response of the lack of innovation in the mental health treatment landscape, as well as the emergence of therapies that may have been overlooked or underused, including psychedelic compounds and digital therapeutics.
atai listed on the NASDAQ stock exchange in June 2021 after a successful fund raising priced at the top of their $13 – $15 range.
Stock information
Contact Information
Latest atai LIFE SCIENCES News
atai Life Sciences Has Been Selected for Addition to the NASDAQ Biotechnology Index
NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of ...
atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update
-Positive topline results from COMP360’s Phase 2b study- -RL-007 Phase 2a topline data in cognitive impairment associated with schizophrenia expected end of Q4- -Continued progress ...
atai Life Sciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Business Update
NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of ...
Perception Neuroscience And Otsuka Pharmaceutical Announce Collaboration On Development Of PCN-101 (R-ketamine) In Japan For Treatment-of Depressive Disorders
Perception Neuroscience (Perception), an atai Life Sciences (atai) biopharmaceutical company focused on developing innovative therapies in neuropsychiatric diseases, today announced positive data from its first ...
